NasdaqGS:BIIB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide.


Snowflake Analysis

Outstanding track record and good value.


Similar Companies

Share Price & News

How has Biogen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIIB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.6%

BIIB

3.4%

US Biotechs

4.3%

US Market


1 Year Return

16.9%

BIIB

26.7%

US Biotechs

7.4%

US Market

Return vs Industry: BIIB underperformed the US Biotechs industry which returned 24.3% over the past year.

Return vs Market: BIIB exceeded the US Market which returned 5% over the past year.


Shareholder returns

BIIBIndustryMarket
7 Day3.6%3.4%4.3%
30 Day-12.0%7.4%0.5%
90 Day-10.4%28.2%23.0%
1 Year16.9%16.9%27.9%26.7%9.7%7.4%
3 Year-1.4%-1.4%34.5%30.1%38.3%29.2%
5 Year-25.1%-31.0%-2.0%-7.5%66.0%47.6%

Price Volatility Vs. Market

How volatile is Biogen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biogen undervalued compared to its fair value and its price relative to the market?

29.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BIIB ($269.8) is trading below our estimate of fair value ($382.36)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BIIB is good value based on its PE Ratio (8.3x) compared to the Biotechs industry average (19.5x).

PE vs Market: BIIB is good value based on its PE Ratio (8.3x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: BIIB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BIIB is overvalued based on its PB Ratio (3.6x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?

-1.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIIB's earnings are forecast to decline over the next 3 years (-1.2% per year).

Earnings vs Market: BIIB's earnings are forecast to decline over the next 3 years (-1.2% per year).

High Growth Earnings: BIIB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BIIB's revenue is expected to decline over the next 3 years (-1.8% per year).

High Growth Revenue: BIIB's revenue is forecast to decline over the next 3 years (-1.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIIB's Return on Equity is forecast to be high in 3 years time (23.2%)


Next Steps

Past Performance

How has Biogen performed over the past 5 years?

10.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIIB has high quality earnings.

Growing Profit Margin: BIIB's current net profit margins (40.8%) are higher than last year (33.8%).


Past Earnings Growth Analysis

Earnings Trend: BIIB's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: BIIB's earnings growth over the past year (25.8%) exceeds its 5-year average (10.1% per year).

Earnings vs Industry: BIIB earnings growth over the past year (25.8%) exceeded the Biotechs industry -4.5%.


Return on Equity

High ROE: BIIB's Return on Equity (46.8%) is considered outstanding.


Next Steps

Financial Health

How is Biogen's financial position?


Financial Position Analysis

Short Term Liabilities: BIIB's short term assets ($8.0B) exceed its short term liabilities ($4.6B).

Long Term Liabilities: BIIB's short term assets ($8.0B) do not cover its long term liabilities ($8.9B).


Debt to Equity History and Analysis

Debt Level: BIIB's debt to equity ratio (47%) is considered high.

Reducing Debt: BIIB's debt to equity ratio has increased from 5% to 47% over the past 5 years.

Debt Coverage: BIIB's debt is well covered by operating cash flow (120.4%).

Interest Coverage: BIIB's interest payments on its debt are well covered by EBIT (106.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Biogen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Michel Vounatsos (58yo)

3.5yrs

Tenure

US$18,159,858

Compensation

Mr. Michel Vounatsos serves as Director at PerkinElmer, Inc. since March 1, 2020. He has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial  ...


CEO Compensation Analysis

Compensation vs Market: Michel's total compensation ($USD18.16M) is above average for companies of similar size in the US market ($USD11.50M).

Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michel Vounatsos
CEO & Director3.5yrsUS$18.16m0.019% $8.6m
Jeffrey Capello
Executive VP & CFO2.58yrsUS$5.81m0.0019% $840.9k
Susan Alexander
Executive VP3.33yrsUS$5.46m0.022% $9.9m
Alfred Sandrock
Executive VP of Research & Development8.42yrsUS$5.31m0.0089% $3.9m
Chirfi Guindo
Executive VP & Head of Global Product Strategy and Commercialization2.67yrsUS$4.69m0.0024% $1.0m
Robin Kramer
VP & Chief Accounting Officer1.67yrsno data0.00014% $61.6k
Mark Hernon
Senior VP & Chief Information Officer2.58yrsno datano data
Joe Mara
VP of Finance and Head of Investor Relationsno datano datano data
F. Edmondson
Chief Corporate & Compliance Counsel and Assistant Secretaryno datano datano data
Ginger Gregory
Executive VP & Chief Human Resources Officer3yrsno data0.0028% $1.2m

2.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: BIIB's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michel Vounatsos
CEO & Director3.5yrsUS$18.16m0.019% $8.6m
Stephen Sherwin
Independent Director10.33yrsUS$411.89k0.0088% $3.9m
Caroline Dorsa
Independent Director10.5yrsUS$416.64k0.012% $5.1m
Stelios Papadopoulos
Independent Chairman of the Board6.08yrsUS$725.31k0.019% $8.5m
Robert Pangia
Independent Director22.83yrsUS$497.10k0.011% $5.0m
Brian Posner
Independent Director12yrsUS$444.64k0.0036% $1.6m
Nancy Leaming
Independent Director12.5yrsUS$421.33k0.0067% $3.0m
Eric Rowinsky
Independent Director10.33yrsUS$411.14k0.0092% $4.1m
Alexander Denner
Independent Director11.08yrsUS$422.64k0.0067% $2.9m
Richard Mulligan
Independent Director11.08yrsUS$401.39k0.0067% $2.9m

10.8yrs

Average Tenure

64yo

Average Age

Experienced Board: BIIB's board of directors are seasoned and experienced ( 10.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biogen Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biogen Inc.
  • Ticker: BIIB
  • Exchange: NasdaqGS
  • Founded: 1978
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$44.028b
  • Shares outstanding: 163.19m
  • Website: https://www.biogen.com

Number of Employees


Location

  • Biogen Inc.
  • 225 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIIBNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 1991
IDPDB (Deutsche Boerse AG)YesCommon StockDEEURSep 1991
IDPXTRA (XETRA Trading Platform)YesCommon StockDEEURSep 1991
BIIBSNSE (Santiago Stock Exchange)YesCommon StockCLUSDSep 1991
BIIB *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNSep 1991
BIIBSWX (SIX Swiss Exchange)YesCommon StockCHCHFSep 1991
BIIB-UETLX (Eurotlx)YesCommon StockITEURSep 1991
BIIBWBAG (Wiener Boerse AG)YesCommon StockATEURSep 1991
BIIB34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REPR 1/6 COM USD0.0005BRBRLApr 2016
BIIBBASE (Buenos Aires Stock Exchange)CEDEAR EACH 13 REP 1 COM USD0.0005ARARSApr 2019

Biography

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/06 23:54
End of Day Share Price2020/07/06 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.